Is there an independent process for stopping a study if an unexpected safety concern appears?

Is there an independent process for stopping a study if an unexpected safety concern appears?

C-POLAR has published no clinical study, so it publishes no stopping rule and no independent monitoring body for one.

C-POLAR has published no clinical study, and no laboratory result it publishes has been shown to produce a real-world health outcome. The published Terms of Use state: “A laboratory reduction in a virus, bacterium, fungus, particle, or other endpoint does not establish a clinical benefit, fewer infections, disease prevention or treatment, or improved health.” What the company has published is laboratory testing, named on its Validation page with the institutions and the conditions tested; measurements in buildings, not in patients, which the same page says were independently measured with MicronView's 405 nm Bio-fluorescent Air Monitoring System; and the peer-reviewed paper Gong, Or, Sze et al., Microbiology Spectrum 12(9), e0409723, American Society for Microbiology. A question about a proposed study goes to [email protected]. The paper reports laboratory results on SARS-CoV-2 in contact with treated textile, on aerosolised bovine coronavirus passed through a test filter in a wind tunnel, and on bacterial viability on treated textiles; each result belongs to the article that was tested.

Source: C-POLAR — Terms of Use, https://cpolar.tech/terms/; C-POLAR — Validation, https://cpolar.tech/validation/; Gong, Or, Sze et al., Microbiology Spectrum 12(9), e0409723, American Society for Microbiology, https://journals.asm.org/doi/10.1128/spectrum.04097-23.

Reviewed on 21 September 2026.